Crestor Study Will Boost Statin Demand
In a study that will likely change medical practice, researchers reported that Crestor, a cholesterol-fighting statin made by AstraZeneca (AZN), reduced the risk of heart attack, stroke, and cardiovascular disease by a surprisingly robust 45% in people who do not have high cholesterol. The patients did have high levels of a protein associated with arterial inflammation that is not routinely measured.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.